Search

Displaying results 261 - 270 of 4297 in total
  1. Drug

    Desmopressin

    go.drugbank.com/drugs/DB00035
    ApprovedInvestigational

    It is considered a first-line therapy for central diabetes insipidus but is ineffective in patients with nephrogenic diabetes insipidus, where the kidneys are non-responsive to the hormone [A275458, L56105 … Additionally, it serves as a critical hematologic agent for the management of mild hemophilia A and von Willebrand disease (Type I) by transiently increasing levels of clotting factors [A31662, A275458

  2. Drug

    Fexofenadine

    go.drugbank.com/drugs/DB00950
    ApprovedInvestigational

    Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H1 receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain...

  3. Drug

    Pilaralisib

    go.drugbank.com/drugs/DB11772
    Investigational

    Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K).

  4. Drug

    Enalapril

    go.drugbank.com/drugs/DB00584
    ApprovedInvestigationalVet approved

    The active metabolite enalaprilat is also available in oral tablets and intravenous formulations for injection. … Commonly marketed under the trade name Vasotec, enalapril was first approved by the FDA in 1985 for the management of hypertension, heart failure, and asymptomatic left ventricular dysfunction.

  5. Drug

    Somatotropin

    go.drugbank.com/drugs/DB00052
    ApprovedInvestigational

    [A228188] Recombinant HGH has been commercially available since 1985 after its development by Genentech. … [Somatrem] was the first available recombinant HGH and was largely replaced by somatropin, another form of recombinant HGH.

  6. Drug

    Esmolol

    go.drugbank.com/drugs/DB00187
    ApprovedInvestigationalWithdrawn

    Other esmolol formulations are still available for use.[L43942] … It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses.

  7. Drug

    Luliconazole

    go.drugbank.com/drugs/DB08933
    ApprovedInvestigational

    Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. … It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.

  8. Drug

    DL-dimyristoylphosphatidylglycerol

    go.drugbank.com/drugs/DB11284
    Approved

    DL-dimyristoylphosphatidylglycerol is a phospholipid used in commercially available pharmaceutical preparations to solubilize drugs for injection.

  9. Drug

    Polymyxin B

    go.drugbank.com/drugs/DB00781
    ApprovedInvestigationalVet approved

    Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. … It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of _Pseudomonas aeruginosa_[FDA Label].

    Mixtures: Bus and Classroom Yellow, Care Bus and Classroom Yellow
  10. Drug

    Panthenol

    go.drugbank.com/drugs/DB11204
    Approved

    Panthenol is an alcohol derivative of pantothenic acid, a component of the B complex vitamins and an essential component of a normally functioning epithelium. Panthenol exists as a racemic mixture containing both the dextrorotatory form ...